Article Text

Download PDFPDF
Medicines update

Statistics from Altmetric.com

The points below highlight changes in marketing authorisations (MAs) that may have a significant impact on veterinary surgeons’ prescribing decisions.

New marketing authorisations

New marketing authorisations relevant to veterinary surgeons in the UK that were issued or published in August 2019 are listed in Table 1.

View this table:
Table 1: Marketing authorisations issued and/or published in August 2019

Of those products listed, the VMD draws attention to:

• HorStem suspension for injection for horses is a novel product containing equine umbilical cord mesenchymal stem cells to treat lameness and other clinical symptoms associated with mild to moderate degenerative joint disease (osteoarthritis) in horses.

In prescribing these veterinary medicines, veterinary surgeons should be aware that changes to the Summary of Product Characteristics, labels and leaflets may, in certain cases, change how the medicines should be used. The timing of when such changes have to be taken into account will depend on the circumstances, but as a general rule unless a prescriber has been advised otherwise by the manufacturer or the VMD the labelling instructions on the pack from which the product is dispensed should be followed.

Table 1 also indicates where a public assessment report should become available for a product. Where available, links to these …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.